MAIA

MAIA Biotechnology Inc.

• NASDAQ·06/26 12:06

  MAIA Completes International Enrollment In Phase 2 THIO-101 Part C For Ateganosine In Lung Cancer

• Benzinga·06/25 12:10

  MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer

• TipRanks·06/22 13:40

  Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)

• TipRanks·06/18 12:47

  MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial

• NASDAQ·06/10 16:30

  MAIA Activates Second U.S. Testing Site In Phase 2 THIO-101 For Ateganosine In Treating Lung Cancer

• NASDAQ·06/05 05:57

  MAIA Advances Phase 3 THIO-104 Trial Of Ateganosine In NSCLC, Targets 100 Patients By Year-End

• TipRanks·06/04 13:50

  MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial

• Benzinga·06/04 13:49

  MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries

• NASDAQ·06/04 08:17

  MAIA Receives FDA Clearance To Expand Phase 2 THIO-101 Lung Cancer Trial In The U.S.

• TipRanks·06/03 13:55

  MAIA Biotechnology receives FDA clearance for amendment to IND application

• Benzinga·06/03 13:47

  MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway

• TipRanks·06/03 02:07

  Top MAIA Biotechnology Insiders Make Bold Moves With Fresh Stock Purchases

• Benzinga·06/02 13:54

  MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K

• TipRanks·06/02 13:50

  Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)

• Benzinga·06/01 12:05

  MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology